Updated:
Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001481512, and its reported...
Overview
Ra Pharmaceuticals, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001481512, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2020-02-27, it reported annual revenue of USD 3,000,000; net income of USD -102,688,000; total assets of USD 284,152,000 for the fiscal period ended 2019-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.
Company overview
- Legal name
- Ra Pharmaceuticals, Inc.
- Classification
- Company
- Industry (SIC)
- 2834 — Pharmaceutical Preparations
- Headquarters
- Cambridge, MA, United States
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 0001481512
Financials
Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.
| Fiscal year | Period end | Revenue | Net income | Total assets | Cash and equivalents | Operating cash flow |
|---|---|---|---|---|---|---|
| FY2019USD | $3.0M | -$102.7M | $284.2M | $265.0M | -$87.4M | |
| FY2018USD | $2.5M | -$64.9M | $219.2M | $209.8M | -$54.9M | |
| FY2017USD | — | -$54.4M | $80.2M | $70.4M | -$46.8M | |
| FY2016USD | $4.9M | -$28.9M | $126.8M | $117.8M | — |
Recent SEC filings
| Form | Filed | Period | Filing |
|---|---|---|---|
| 10-K/A | 10-K/A | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 10-K | 10-K | ||
| 8-K | FORM 8-K | ||
| 8-K | FORM 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K | ||
| 10-Q | 10-Q | ||
| 8-K | 8-K |
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Research Ra Pharmaceuticals, Inc. in Altss
Track this company’s investors, transactions and relationships in Altss.